Considering that the expression of MYL9 can affect the response of patients with CRC to immunotherapy, we used GSE78220 (n = 28), GSE19423 (n = 48), Miao et al. [14] (n = 35), and IMvirgor210 (n = 298) cohorts to study whether MYL9 expression can predict patients’ response to immunotherapy. Here, MYL9 is linked to colorectal carcinoma.